Laryngeal papillomatosis future or investigational therapies

Scientists and clinicians are working to discover more about laryngeal papillomatosis. While HPV 6 and HPV 11 are known causes, millions of people are exposed to these two viruses without developing the disease. It is not known why some people are more at risk than others or why some cases are much more serious than others.

Researchers funded by the National Institute on Deafness and Other Communication Disorders (NIDCD) are exploring how our genes and immune system may contribute to our risk for contracting the disease as well as the severity of its symptoms. Researchers are also studying other possible therapies for laryngeal papillomatosis. In one clinical trial, researchers are investigating whether a common anti-inflammatory drug can inhibit an enzyme that promotes tumor growth in laryngeal papillomatosis, thus reducing the recurrence of tumors in children and adults with laryngeal papillomatosis. Researchers are also investigating the effectiveness of a pulsed dye laser, a laser that delivers short intense pulses of light, to determine if it is more effective at preserving the surrounding tissue while removing tumors from vocal folds. In one NIDCD- sponsored clinical investigation, researchers are studying whether a certain dietary supplement can work with the pulsed dye laser to decrease the rate of recurrence of tumors in children with laryngeal papillomatosis. To read about these and other clinical trials, go to Pulsed Dye Laser for Juvenile Onset Recurrent Respiratory Papillomatosis.

Template:WH Template:WS